UK charity donates generous funding for eye disease treatment

Article

Fight for Sight has donated £1.6 million towards ten research grants focused on tackling sight loss and eye disease treatment.

Fight for Sight has donated £1.6 million towards ten research grants focused on tackling sight loss and eye disease treatment.

The research grants will be given to a clinical fellowship, two early career investigator awards and seven project grants. Work will begin universities and hospitals across the UK and aims to develop treatment for age-related macular degeneration, glaucoma, eyelid cancer, inherited paediatric retinal disease and diabetic retinopathy.

Dr Dolores Conroy, Director of Research at Fight for Sight, commented, "Currently, there are a huge number of eye conditions that we do not know enough about, and which have few treatment options – such as age-related macular degeneration and diabetic retinopathy. It is therefore crucial that we invest as much as we can into research, which could bring us closer to finding new ways to help people living with sight loss. We hope our commitment to funding pioneering research will bring us even closer to a future everyone can see.”

To find out more about the charity please click here

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.